Top Stories· August 18, 2026 at 02:00 p.m.
Roche Canada and pCPA Reach Agreement on Perjeta® for Aggressive Early Breast Cancer Treatment
Key takeaways
- Perjeta® approved for neoadjuvant treatment of aggressive early stage breast cancer
- Roche Canada and pCPA reached an agreement on Perjeta® costs
- Clinical trials showed significant reduction in disease recurrence or death with Perjeta®
The agreement is expected to benefit thousands of Canadian breast cancer patients each year. It underscores the ongoing efforts by pharmaceutical companies and health authorities to improve treatment options for patients with aggressive forms of breast cancer.
